<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02139800</url>
  </required_header>
  <id_info>
    <org_study_id>819208</org_study_id>
    <secondary_id>1U01HD072906-01A1</secondary_id>
    <nct_id>NCT02139800</nct_id>
  </id_info>
  <brief_title>Sustained Aeration of Infant Lungs Trial</brief_title>
  <acronym>SAIL</acronym>
  <official_title>Sustained Aeration of Infant Lungs Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a 2-arm randomized, controlled, multi-center clinical trial to determine which
      of two strategies at birth are best to optimally aerate the lung of preterm infants.
      Specifically we will determine in 600 infants of 23-26 weeks gestational age (GA) requiring
      respiratory support at birth which of two lung opening strategies - either a standard
      PEEP/CPAP of 5-7 cm H2O in the delivery room (DR), as compared to early lung recruitment
      using Sustained Inflation (SI) in the DR, will result in a lower rate of the combined
      endpoint of death or bronchopulmonary dysplasia (BPD) at 36 weeks gestational age.

      Hypotheses:

        1. Early lung recruitment with SI superimposed upon standard PEEP/CPAP in the DR will
           reduce the need for mechanical ventilation in the first seven days of life, and reduce
           need for surfactant use; and

        2. A policy of DR SI on standard PEEP/CPAP recruitment will confer better outcomes at 36
           weeks post-menstrual age (PMA) than standard PEEP/CPAP
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SAIL trial aims to provide evidence for changing policy or standard of care. The context
      of this trial is an unacceptable rate of poor long-term outcomes of preterm infants born as
      Extremely Low Gestational Age Newborns (ELGAN) &lt;1000 g birthweight (BW), but especially for
      those born between 23-26 weeks' gestational age (GA). Such infants are the most vulnerable
      and immature in all organ systems, including the lungs and the brain. These infants are at
      high risk of death and bronchopulmonary dysplasia (BPD) during their initial hospitalization,
      neurodevelopmental impairment (NDI) and pulmonary problems in infancy and childhood.

      The SAIL trial focuses on facilitating the difficult transition of these most vulnerable
      infants from a liquid filled in-utero lung to an ex-utero air-filled lung. Sustained
      Inflation (SI) is a promising delivery room (DR) intervention, with evidence of short-term
      efficacy with minimal risk of additional harm beyond current standard accepted Newborn
      Resuscitation Program (NRP) Guidelines. This protocol proposes a fully informed consenting
      procedure. We propose to evaluate the impact of a SI in the DR on the need for mechanical
      ventilation in the first week of life which would also impact mortality rates and the
      incidence and severity of BPD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2014</start_date>
  <completion_date type="Actual">March 23, 2020</completion_date>
  <primary_completion_date type="Actual">February 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined Outcome of Death or Bronchopulmonary Dysplasia</measure>
    <time_frame>36 weeks</time_frame>
    <description>To determine in infants born at 23-26 weeks gestational age requiring respiratory support at birth, which of two treatment strategies when compared, results in a lower rate of the combined endpoint of death or bronchopulmonary dysplasia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygen Profile Over First 24 Hours</measure>
    <time_frame>First 24 hours post delivery</time_frame>
    <description>Oxygen profile over first 24 hours post delivery room using hourly FiO2 records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Profile With Highest FiO2 Level up to 48 Hours</measure>
    <time_frame>48 hours of life</time_frame>
    <description>Highest FiO2 level recorded during the first 48 hours post DR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate in the Delivery Room (DR)</measure>
    <time_frame>First 30 seconds of life in DR</time_frame>
    <description>Categorical variable with 3 levels: &lt;60, 60-100, &gt;100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detailed Status on Departure From the Delivery Room (DR)</measure>
    <time_frame>Resuscitation time will vary - 1 to 30 minutes</time_frame>
    <description>Type of respiratory support (CPAP, PPV) and Fraction of Inspired Oxygen (FiO2) on departure from DR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Inotropes on Arrival in NICU</measure>
    <time_frame>First 48 hours of life</time_frame>
    <description>Circulatory support post-delivery room</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Intubation in Delivery Room</measure>
    <time_frame>First 30 seconds to 24 hours of life</time_frame>
    <description>Need for intubation in delivery room during the first 30 seconds to 24 hours of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure-volume Characteristics in the Delivery Room (DR)</measure>
    <time_frame>Expected average 30 minutes</time_frame>
    <description>Pressure-volume characteristics in the Delivery room (DR) expected within 30 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumothorax or New Chest Drains in the First 48 Hours of Life</measure>
    <time_frame>First 48 hours of life</time_frame>
    <description>Chest x-ray reports showing pneumothorax or new chest drains in the first 48 hours of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Any Chest Drain In-situ Post-DR</measure>
    <time_frame>During hospitalization - up to 36 weeks Post Menstrual Age (PMA)</time_frame>
    <description>Duration of any chest drain in-situ post-DR during hospitalization - up to 36 weeks Post Menstrual Age (PMA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraventricular Hemorrhage by All Grades</measure>
    <time_frame>48 hours to 10 days</time_frame>
    <description>Head ultrasound and/or MRI findings of intraventricular hemorrhage by all grades focusing on grades 3 and 4 by 48 hour and by day 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest X-ray Between Days 7-10</measure>
    <time_frame>First 7-10 days of life</time_frame>
    <description>Chest x-ray between the first 7-10 days of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or Need for Positive Pressure Ventilation</measure>
    <time_frame>First 7 days of life</time_frame>
    <description>Death or need for positive pressure ventilation during the first 7 days of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest FiO2 and Area Under the FiO2 Curve for the First Week of Life</measure>
    <time_frame>First 7 days of life</time_frame>
    <description>Highest FiO2 and Area under the FiO2 curve during the first 7 days of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumothorax and Pulmonary Interstitial Emphysema (PIE)</measure>
    <time_frame>First 10 days of life</time_frame>
    <description>Pneumothorax and pulmonary interstitial emphysema (PIE) during the first 10 days of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival to Discharge Home Without BPD, Retinopathy of Prematurity (Grades 3 &amp; 4), or Significant Brain Abnormalities on Head Ultrasound</measure>
    <time_frame>Expected discharge between 36 - 40 weeks PMA</time_frame>
    <description>Survival to discharge home without BPD, retinopathy of prematurity (grades 3 &amp; 4), or significant brain abnormalities on head ultrasound with an expected discharge between 36-40 weeks PMA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Respiratory Support (Ventilation, CPAP, Supplemental Oxygen)</measure>
    <time_frame>During hospitalization - up to 36 weeks Post Menstrual Age (PMA)</time_frame>
    <description>Duration of respiratory support (ventilation, CPAP, supplemental oxygen) during hospitalization upto 36 weeks Post Menstrual Age (PMA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death in Hospital</measure>
    <time_frame>During expected hospitalization 23 - 40 weeks PMA</time_frame>
    <description>Death in hospital during expected hospitalization of 23-40 weeks PMA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinopathy of Prematurity (ROP) Stage 3 or Greater Requiring Treatment</measure>
    <time_frame>36 weeks</time_frame>
    <description>Retinopathy of prematurity (ROP) stage 3 or greater requiring treatment at 36 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Postnatal Steroids for Treatment of BPD</measure>
    <time_frame>During hospitalization - up to 36 weeks Post Menstrual Age (PMA)</time_frame>
    <description>Use of postnatal steroids for treatment of BPD during hospitalization up to 36 weeks Post Menstrual Age (PMA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>Average discharge between 36 - 40 weeks PMA</time_frame>
    <description>Length of hospital stay with average discharge between 36-40 weeks PMA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopmental and Respiratory Outcome at 22-26 Months Corrected Gestational Age</measure>
    <time_frame>22-26 months corrected gestational age</time_frame>
    <description>Neurodevelopmental and respiratory outcome at 22-26 months corrected gestational age</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">460</enrollment>
  <condition>Preterm Birth</condition>
  <condition>Extreme Prematurity</condition>
  <arm_group>
    <arm_group_label>Control Arm-Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Arm-Respiratory support using Standard of Care positive-end expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O compared to Sustained Inflation intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sustained Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer delivery room respiratory support using a Sustained Inflation (SI) intervention and expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sustained Inflation</intervention_name>
    <description>The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds</description>
    <arm_group_label>Sustained Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention</description>
    <arm_group_label>Control Arm-Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age (GA) at least 23 weeks but less than 27 completed weeks by best
             obstetrical estimate

          -  Requiring resuscitation/respiratory intervention at birth -&quot;apneic, labored breathing,
             gasping&quot; (as defined in NRP 2011 AAP 6th Edition p.45)

        Exclusion Criteria:

          -  Considered non-viable by the attending neonatologist

          -  Refusal of antenatal informed consent

          -  Known major anomalies, pulmonary hypoplasia

          -  Mothers who are unable to consent for their medical care and who do not have a
             surrogate guardian will not be approached for consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Weeks</minimum_age>
    <maximum_age>26 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haresh Kirpalani, BM, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Davis, MD, FRAXP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Women's Hospital, Melbourne, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helmut Hummler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital, University of Ulm, Ulm Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Keszler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women &amp; Infants Hospital of Rhode Island, Providence, RI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GianLuca Lista, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale dei Bambini, Milan Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arjan te_Pas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center, Leiden, Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Children's Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Mary Birch Hospital for Women &amp; Newborns</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Med Health</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the Univerity of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Mother's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>QLD 4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Women's Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Teaching Hospital, Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra Hospital,</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, University of Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale dei Bambini</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Children's Hospit</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emma Children's Hospital, AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KK Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>168753</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 8, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2014</study_first_posted>
  <results_first_submitted>June 5, 2020</results_first_submitted>
  <results_first_submitted_qc>June 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2020</results_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neonatal resuscitation</keyword>
  <keyword>Extreme Low Gestational Age Newborn (ELGAN)</keyword>
  <keyword>Delivery Room</keyword>
  <keyword>Continuous positive airway pressure (CPAP)</keyword>
  <keyword>Positive pressure ventilation (PPV)</keyword>
  <keyword>Sustained inflation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT02139800/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 14, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT02139800/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Arm-Standard of Care</title>
          <description>Control Arm-Respiratory support using Standard of Care positive-end expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O compared to Sustained Inflation intervention
Standard of Care: Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention</description>
        </group>
        <group group_id="P2">
          <title>Sustained Intervention</title>
          <description>Administer delivery room respiratory support using a Sustained Inflation (SI) intervention and expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O
Sustained Inflation: The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="236"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
                <participants group_id="P2" count="215"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Arm-Standard of Care</title>
          <description>Control Arm-Respiratory support using Standard of Care positive-end expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O compared to Sustained Inflation intervention
Standard of Care: Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention</description>
        </group>
        <group group_id="B2">
          <title>Sustained Intervention</title>
          <description>Administer delivery room respiratory support using a Sustained Inflation (SI) intervention and expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O
Sustained Inflation: The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="211"/>
            <count group_id="B2" value="215"/>
            <count group_id="B3" value="426"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Infants were included in the study based on their gestational age. - include GA strata</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>23-24 weeks GA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25-26 weeks GA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>The sex of the infants are included below.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Maternal race/ethnicity is listed below</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Consent Type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Antenatal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deferred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maternal Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.5" lower_limit="26.0" upper_limit="34.9"/>
                    <measurement group_id="B2" value="31.1" lower_limit="26.5" upper_limit="35.4"/>
                    <measurement group_id="B3" value="30.9" lower_limit="26.3" upper_limit="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Combined Outcome of Death or Bronchopulmonary Dysplasia</title>
        <description>To determine in infants born at 23-26 weeks gestational age requiring respiratory support at birth, which of two treatment strategies when compared, results in a lower rate of the combined endpoint of death or bronchopulmonary dysplasia.</description>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm-Standard of Care</title>
            <description>Control Arm-Respiratory support using Standard of Care positive-end expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O compared to Sustained Inflation intervention
Standard of Care: Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention</description>
          </group>
          <group group_id="O2">
            <title>Sustained Intervention</title>
            <description>Administer delivery room respiratory support using a Sustained Inflation (SI) intervention and expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O
Sustained Inflation: The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds</description>
          </group>
        </group_list>
        <measure>
          <title>Combined Outcome of Death or Bronchopulmonary Dysplasia</title>
          <description>To determine in infants born at 23-26 weeks gestational age requiring respiratory support at birth, which of two treatment strategies when compared, results in a lower rate of the combined endpoint of death or bronchopulmonary dysplasia.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen Profile Over First 24 Hours</title>
        <description>Oxygen profile over first 24 hours post delivery room using hourly FiO2 records</description>
        <time_frame>First 24 hours post delivery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen Profile With Highest FiO2 Level up to 48 Hours</title>
        <description>Highest FiO2 level recorded during the first 48 hours post DR</description>
        <time_frame>48 hours of life</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate in the Delivery Room (DR)</title>
        <description>Categorical variable with 3 levels: &lt;60, 60-100, &gt;100</description>
        <time_frame>First 30 seconds of life in DR</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Detailed Status on Departure From the Delivery Room (DR)</title>
        <description>Type of respiratory support (CPAP, PPV) and Fraction of Inspired Oxygen (FiO2) on departure from DR</description>
        <time_frame>Resuscitation time will vary - 1 to 30 minutes</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Inotropes on Arrival in NICU</title>
        <description>Circulatory support post-delivery room</description>
        <time_frame>First 48 hours of life</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Intubation in Delivery Room</title>
        <description>Need for intubation in delivery room during the first 30 seconds to 24 hours of age</description>
        <time_frame>First 30 seconds to 24 hours of life</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pressure-volume Characteristics in the Delivery Room (DR)</title>
        <description>Pressure-volume characteristics in the Delivery room (DR) expected within 30 minutes</description>
        <time_frame>Expected average 30 minutes</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumothorax or New Chest Drains in the First 48 Hours of Life</title>
        <description>Chest x-ray reports showing pneumothorax or new chest drains in the first 48 hours of life</description>
        <time_frame>First 48 hours of life</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Any Chest Drain In-situ Post-DR</title>
        <description>Duration of any chest drain in-situ post-DR during hospitalization - up to 36 weeks Post Menstrual Age (PMA)</description>
        <time_frame>During hospitalization - up to 36 weeks Post Menstrual Age (PMA)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraventricular Hemorrhage by All Grades</title>
        <description>Head ultrasound and/or MRI findings of intraventricular hemorrhage by all grades focusing on grades 3 and 4 by 48 hour and by day 10</description>
        <time_frame>48 hours to 10 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chest X-ray Between Days 7-10</title>
        <description>Chest x-ray between the first 7-10 days of life</description>
        <time_frame>First 7-10 days of life</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death or Need for Positive Pressure Ventilation</title>
        <description>Death or need for positive pressure ventilation during the first 7 days of life</description>
        <time_frame>First 7 days of life</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest FiO2 and Area Under the FiO2 Curve for the First Week of Life</title>
        <description>Highest FiO2 and Area under the FiO2 curve during the first 7 days of life</description>
        <time_frame>First 7 days of life</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumothorax and Pulmonary Interstitial Emphysema (PIE)</title>
        <description>Pneumothorax and pulmonary interstitial emphysema (PIE) during the first 10 days of life</description>
        <time_frame>First 10 days of life</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival to Discharge Home Without BPD, Retinopathy of Prematurity (Grades 3 &amp; 4), or Significant Brain Abnormalities on Head Ultrasound</title>
        <description>Survival to discharge home without BPD, retinopathy of prematurity (grades 3 &amp; 4), or significant brain abnormalities on head ultrasound with an expected discharge between 36-40 weeks PMA</description>
        <time_frame>Expected discharge between 36 - 40 weeks PMA</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Respiratory Support (Ventilation, CPAP, Supplemental Oxygen)</title>
        <description>Duration of respiratory support (ventilation, CPAP, supplemental oxygen) during hospitalization upto 36 weeks Post Menstrual Age (PMA)</description>
        <time_frame>During hospitalization - up to 36 weeks Post Menstrual Age (PMA)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death in Hospital</title>
        <description>Death in hospital during expected hospitalization of 23-40 weeks PMA</description>
        <time_frame>During expected hospitalization 23 - 40 weeks PMA</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retinopathy of Prematurity (ROP) Stage 3 or Greater Requiring Treatment</title>
        <description>Retinopathy of prematurity (ROP) stage 3 or greater requiring treatment at 36 weeks</description>
        <time_frame>36 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Postnatal Steroids for Treatment of BPD</title>
        <description>Use of postnatal steroids for treatment of BPD during hospitalization up to 36 weeks Post Menstrual Age (PMA)</description>
        <time_frame>During hospitalization - up to 36 weeks Post Menstrual Age (PMA)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <description>Length of hospital stay with average discharge between 36-40 weeks PMA</description>
        <time_frame>Average discharge between 36 - 40 weeks PMA</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurodevelopmental and Respiratory Outcome at 22-26 Months Corrected Gestational Age</title>
        <description>Neurodevelopmental and respiratory outcome at 22-26 months corrected gestational age</description>
        <time_frame>22-26 months corrected gestational age</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from birth to discharge, death or 44 weeks PMA whichever occurred first</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control Arm-Standard of Care</title>
          <description>Control Arm-Respiratory support using Standard of Care positive-end expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O compared to Sustained Inflation intervention
Standard of Care: Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention</description>
        </group>
        <group group_id="E2">
          <title>Sustained Intervention</title>
          <description>Administer delivery room respiratory support using a Sustained Inflation (SI) intervention and expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O
Sustained Inflation: The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Within the first 48 hours post delivery</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <description>Within the first 10 days of life</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Grade 3 or 4 IVH</sub_title>
                <description>Within the first 10 days of life</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Interstitial Emphysemia (PIE)</sub_title>
                <description>Within the first 10 days of life</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Administration of epinephrine or chest compressions</sub_title>
                <description>Within the first 48 hours post delivery</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>IVH Grade 1/2 within first 10 days of life</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>FiO2&gt;=0.4 for &gt;=2 hrs in first 2 DOL</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>&gt;30% oxygen at 28 days of life</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Mechanical support at 28 days of life</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Haresh Kirpalani</name_or_title>
      <organization>Children's Hospital of Philadelphia (CHOP)</organization>
      <phone>215-590-2455</phone>
      <email>kirpalanih@email.chop.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

